10^th International Conference on Molecular & Cellular Cardiology November 28-29, 2017 Sao Paulo, Brazil

Sympathetic nerve activity has been reported to be increased in both humans and animals with chronic heart failure. One of the mechanisms believed to be responsible for this phenomenon is increased systemic and cerebral angiotensin II signaling. Plasma angiotensin II is increased in humans and animals with chronic heart failure. Blocking angiotensin II type 1 receptors decreases sympathetic nerve activity and cardiac sympathetic afferent reflex when therapy is administered to the paraventricular nucleus.. Cardiac fibroblasts (CF) are well-established as key regulators of extracellular matrix (ECM) turnover in the context of myocardial remodelling and fibrosis. The increasing availability of detailed, atrial-specific experimental data has stimulated the development of novel computational models of atrial-cellular electrophysiology and Ca²⁺ -handling. Dysregulation of autophagy in cardiomyocytes is implicated in various heart disease conditions. Beclin 1, a mammalian ortholog (Genes of different species that evolved from common ancestral gene).

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

A noninvasive  method for studying cardiovascular disease by use of nuclear imaging techniques. These examinations are usually done while the individual is exercising. Coronary artery disease can be investigated as can damage to the myocardium following coronary infarction. The size and function of the ventricles can be evaluated using these techniques. It makes possible primarily functional assessment of the heart with quantification of perfusion and systolic function. Development of new types of scanners for nuclear cardiology brings more possibilities in research and clinical practice. This paper describes a brief review of some applications of cadmium–zinc–telluride (CZT) scanners in comparison with conventional cameras.

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

Cardio-oncology, or onco-cardiology, is the discipline that focuses on the intersection of cardiovascular disease and cancer. With the prognosis for many cancers improving, we are seeing an appropriate sharpening of focus on the cardiovascular risks of patients who have survived cancer or are being treated for cancer, as well as a growing recognition of the impact this competing morbidity has on both short- and long-term health outcomes.

Arrhythmia/cardiac dysrhythmia means irregular heart beats or heart rhythm where muscles of heart contract in a coordinated fashion to insure that blood is been efficiently pumped into the arteries and the extra heart beat are due to premature atrial contraction and premature ventricular contraction. Cardiac cirrhosis (congestive hepatopathy) includes a spectrum of hepatic derangements that occur in the setting of right-sided heart failure. Clinically, the signs and symptoms of congestive heart failure (CHF) dominate the disorder. Unlike cirrhosis caused by chronic alcohol use or viral hepatitis, the effect of cardiac cirrhosis on overall prognosis has not been clearly established. As a result, treatment is aimed at managing the underlying heart failure. A separate theory proposes that cardiac cirrhosis is not simply a response to chronically increased pressure and sinusoidal stasis. Because intrahepatic vascular lesions are confined to areas of the liver with higher fibrotic burden, cardiac cirrhosis may require a higher grade of vascular obstruction, such as intrahepatic thrombosis, for its development.

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

Interventional cardiology is a branch of cardiology that deals specifically with the catheter based treatment of structural heart diseases. Interventional cardiology refers to diagnostics and non-surgical treatments of the heart.
Translational medicine is a rapidly growing discipline in biomedical research and aims to expedite the discovery of new diagnostic tools and treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach. Within public health, translational medicine is focused on ensuring that proven strategies for disease treatment and prevention are actually implemented within the community.

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

Cardiogenic pulmonary edema (CPE) is defined as pulmonary edema due to increased capillary hydrostatic pressure secondary to elevated pulmonary venous pressure. CPE reflects the accumulation of fluid with a low-protein content in the lung interstitium and alveoli as a result of cardiac dysfunction. CPE leads to progressive deterioration of alveolar gas exchange and respiratory failure. Without prompt recognition and treatment, a patient's condition can deteriorate rapidly. The major complications associated with CPE are respiratory fatigue and failure.

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

Cardiac aging is a heterogeneous process caused by a combination of stochastic events which manifests as loss of structure and function in the heart, however several recent studies draw attention to aging being primarily a stem cell problem. Autophagy, a cellular housekeeping process, is essential to maintain tissue homeostasis, particularly in long-lived cells such as cardiomyocytes. Autophagic activity declines with age and may explain many features of age-related cardiac dysfunction. Impaired autophagic clearance of protein aggregates or deteriorating mitochondria will have multiple consequences including increased arrhythmia risk, decreased contractile function, reduced tolerance to ischemic stress, and increased inflammation; thus autophagy represents a potentially important therapeutic target to mitigate the cardiac consequences of aging. Aging results in progressive deteriorations in the structure and function of the heart and is a dominant risk factor for cardiovascular diseases, the leading cause of death in Western populations.

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

Hypertension (HTN or HT), also known as high blood pressure, is a long term medical condition in which the blood pressure in the arteries is persistently elevated.^[1] High blood pressure usually does not cause symptoms.^[2] Long term high blood pressure; however, is a major risk factor for coronary artery disease, stroke, heart failure, peripheral vascular disease, vision loss, and chronic kidney disease.Cardiac progenitor cells (CPCs) are committed to the cardiac lineage but retain their proliferative capacity before becoming quiescent mature cardiomyocytes (CMs). In medical therapy and research, the use of human pluripotent stem cell-derived CPCs would have several advantages compared with mature CMs, as the progenitors show better engraftment into existing heart tissues, and provide unique potential for cardiovascular developmental as well as for pharmacological studies. Cardiac progenitor cells (CPCs) represent the earliest stages of mesoderm commitment to the cardiac lineages and directed differentiation of CPCs from pluripotent stem cells has been demonstrated in a number of recent studies. Furthermore, these cells have been shown to be capable of generating other terminal cardiac cell types such as cardiomyocytes, endothelial cells, and vascular smooth muscle cells.  However, utilization of CPCs for such endeavors requires a robust, scalable, and consistent differentiation methodology.

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

Heart failure, sometimes known as congestive heart failure, occurs when your heart muscle doesn't pump blood as well as it should. Common causes of heart failure include coronary artery disease including a previous myocardial infarction (heart attack), high blood pressure, atrial fibrillation, valvular heart disease, excess alcohol use, infection, and cardiomyopathy of an unknown cause. Atrial fibrillation is the most common serious abnormal heart rhythm. Rapid and irregular heart rates may be perceived as palpitations or exercise intolerance and occasionally may produce anginal chest pain.

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

Cardiac hypertrophy is defined as an increase in the size of the heart caused by an increase in the size of the cardiomyocytes therein, which is achieved by an increase in the number of sarcomeres, a basic unit of a muscle's cross-striated myofibril. Cardiac hypertrophy is caused by hemodynamic overload, which includes pressure overload (PO) caused by aortic stenosis and high blood pressure, and volume overload (VO) caused by valvular insufficiency, chronic myocardial infarction, arteriovenous shunt, and pregnancy. PO causes “concentric” hypertrophy, characterized by increased ventricular wall thickness and little chamber dilation, where parallel addition of sarcomeres increases the size of cardiomyocytes in both minor and major axes. In contrast, VO results in “eccentric” hypertrophy, characterized by increased ventricular volume with little increase in the wall thickness, where serial addition of sarcomeres increases the size of cardiomyocytes primarily by elongation.

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

Cardiac imaging techniques include coronary catheterization, echocardiogram, Intravascular ultrasound, Cardiac PET scan,Cardiac CT scan and Cardiac MRI.

Various intrinsic, neural, and hormonal factors act to influence the rhythm control and impulse conduction within the heart. The rhythmic control of the cardiac cycle and its accompanying heartbeat relies on the regulation of impulses generated and conducted within the heart. Regulation of the cardiac cycle is also achieved via the autonomic nervous system. The sympathetic and parasympathetic divisions of the autonomic system regulate heart rhythm by affecting the same intrinsic impulse conducting mechanisms that lie within the heart in opposing ways. The cardiovascular system is subject to precise reflux regulation so that an appropriate supply of oxygenated blood can be reliably provided to different body tissues under a wide range of circumstances. The sensory monitoring for this critical homeostatic process entails primarily mechanical (barosensory) information about pressure in the arterial system and, secondarily, chemical (chemosensory) information about the level of oxygen and carbon dioxide in the blood. The parasympathetic and sympathetic activity relevant to cardiovascular control is determined by the information supplied by these sensors.

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

Molecular cardiology is a new and fast-growing area of cardiovascular medicine that aims to apply molecular biology techniques for the mechanistic investigation, diagnosis, prevention and treatment of cardiovascular disease. As an emerging discipline, it has changed conceptual thinking of cardiovascular development, disease etiology and pathophysiology. Although molecular cardiology is still at a very early stage, it has opened a promising avenue for understanding and controlling cardiovascular disease. With the rapid development and application of molecular biology techniques, scientists and clinicians are closer to curing heart diseases that were thought to be incurable 20 years ago. There clearly is a need for a more thorough understanding of the molecular mechanisms of cardiovascular diseases to promote the advancement of stem cell therapy and gene therapy for heart diseases. 

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

Cardiac involvement is the most important cause of death in patients with sarcoidosis, yielding a 5-year mortality risk up to 66% despite appropriate immunosuppressive treatment. Early diagnosis and prompt initiation of corticosteroid therapy in this population has proven to improve left ventricular (LV) function though, at the same time reducing risk of malignant arrhythmia. Recently, two-dimensional speckle-tracking echocardiography has been introduced as a new and highly sensitive echocardiographic technique to assess regional and global biventricular performance, detecting myocardial tissue diseases even in the pre-clinical stage. We report a histology proven case of cardiac sarcoidosis in which strain curves of each LV segment were matched to macroscopic findings of the explanted heart, with the aim to test accuracy of deformation imaging in identifying specific areas involved by myocardial infiltration/inflammation.

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.

Entrepreneurs  is an individual who, rather than working as an employee, runs a small business and assumes all the risk and reward of a given business venture, idea, or good or service offered for sale. The Cardio vascular Devices entrepreneur is commonly seen as a business leader and innovator of new ideas and business processes working on Medical devices. Entrepreneurs play a key role in any economy. These are the people who have the skills and initiative necessary to take good new ideas to cardiothoracic devices market and make the right decisions to make the idea profitable. Cardiac Devices Entrepreneurs Investment Meeting is a gathering of Cardiac Devices. Entrepreneurs and Investors that has been convened for the purpose of achieving a common goal through verbal interaction, such as sharing information or reaching agreement.

Related Conferences

7^th World Cardiothoracic Meeting March 29-30, 2016 Atlanta, USA; Echo Cardiography Conference June 06-07, 2016 London, UK; Ischemic Heart Diseases Conference May 12-13, 2016 Chicago, USA; 8^th Global Cardiologists Annual Meeting July 18-20, 2016 Berlin, Germany; Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; Drug Discovery and Therapy World Congress May 11-14, 2016, Boston, USA; 7^th International Conference on Drug Discovery and Therapy, February 15-18, 2016 Dubai, UAE; Arrhythmias & the Heart: A Cardiovascular Update, February 12–16, 2016, Riyadh, Saudi Arabia; 16^th Annual International Symposium on Congenital Heart Disease, February 13–16, 2016, St. Petersburg, USA; Cardiovascular Conference at Snowbird, February 12-15, 2016, Snowbird, Utah; Korean Cardiology Related Societies Joint Scientific Congress, April 15-16, 2016, Daegu, Korea.